Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATENT-CHILD: Riociguat in Children With Pulmonary Arterial Hypertension
NCT02562235Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Oct 2015
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of riociguat in pulmonary arterial hypertension (PAH), sponsored by Bayer. Started Oct 2015; status: active, not recruiting.
02
Drugs
riociguat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02562235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02562235.